The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will organize ISPOR Europe 2023 on 12-15 November 2023 in Copenhagen, Denmark.
Healthcare policy is evolving rapidly to address issues around the use of real-world evidence (RWE), cross-border collaboration, affordability, and equity. ISPOR Europe 2023 will address these issues and more, with a sharp focus on the role of health economics and outcomes research (HEOR) science in shaping policy. In Europe as well as globally, the use of RWE by regulatory, health technology assessment (HTA), and payer bodies relies heavily on the underlying science to improve and verify data quality and linkages, allow for causal inference, and protect privacy. International collaboration, particularly for HTA purposes, is strengthened by agreement on outcome measurement, evaluation methods, and transferability of evidence. Achieving affordability and equity, while maintaining incentives for innovation, requires proper measurement and evaluation of both societal benefits and costs of healthcare.
At ISPOR Europe 2023 (#ISPOREurope), HARMONY Partner Katharina Lang, Charité – Universitätsmedizin Berlin, will be presenting a poster titled:
Updated Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies in the framework of the EU project - HARMONY - the Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology
The HARMONY Alliance and Health Economics and Outcomes Research
Regulatory agencies and health technology assessment bodies require robust evidence to show that drug treatment is both effective and safe. In the case of rare diseases, it may be difficult for researchers to generate sufficient evidence, especially on how effective the treatment is compared with other available treatments. The lack of evidence may hinder market access and the subsequent reimbursement of treatments for these conditions, and slow down or even block patient access to novel treatments. The HARMONY Alliance aims to help researchers develop appropriate mitigation strategies for new treatments for Hematological Malignancies.
#Bigdataforbloodcancer: Revolutionizing the use of big data in Hematologic Malignancies research.
When the HARMONY Alliance started in 2017, the hematology community was embarking on a journey towards embracing data sharing and recognizing the transformative power of big data. HARMONY set a crucial milestone when this endeavor was only starting. By laying the foundation for future collaborations, advancements, and discoveries that would incorporate state-of-the-art technologies in the field of hematology, HARMONY is making its contribution to improve the understanding and treatment of blood disorders. Now, just almost seven years later with 128 partners from 28 countries, we have transformed both the sharing and use of data. We have developed the Big Data Platform with a data lake that has identified over 160,000 patient records. All data is protected using a unique anonymization and security process. In more than 30 research projects, groundbreaking research is being carried out with the help of advanced customized data analytic services, including AI modelling.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
